[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"allogeneic-blood-and-marrow-transplantation-bmt\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:allogeneic-blood-and-marrow-transplantation-bmt":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100615167","patient-reported-outcomes-in-allogeneic-stem-cell-transplantation-and-car-t-therapy-100615167",false,"NCT07289087","Patient-Reported Outcomes in Allogeneic Stem Cell Transplantation and CAR-T Therapy","A Real-World Observational Study on Patient-Reported Outcomes in Allogeneic Stem Cell Transplantation (Allo-SCT) and CAR-T Therapy","QOL-ONE PRO-CT","Inclusion Criteria:\n\n* Diagnosed with a hematologic malignancy (e.g., leukemia, lymphoma, multiple myeloma)\n* Undergoing either allogeneic SCT or CAR-T therapy\n* Able and willing to provide written informed consent\n* Sufficient Italian proficiency to complete the HM-PRO\n* Signed informed consent\n\nExclusion Criteria:\n\n* Cognitive or physical impairments that preclude the ability to complete questionnaires\n* Estimated life expectancy \\\u003C 7 days at the time of admission","ALL","18 Years",{"count":20,"type":21},162,"ESTIMATED","OBSERVATIONAL","3.1. Overview Prospective, multicenter, observational cohort study comparing short-term PROs measured with the HM-PRO between two exposure groups: patients undergoing allogeneic stem cell transplantation (allo-SCT) and patients receiving CAR-T cell therapy. Patients will be enrolled at hospital admission for the index inpatient procedure and followed through the inpatient stay (admission → discharge). The study is non-randomized and designed to describe trajectories of symptoms and HRQoL and to estimate the between-group difference in deterioration of HM-PRO scores (primary estimand: mean difference in change score, CAR-T vs allo-SCT).",[25,26,27,28],"Quality of Life","Patient Reported Outcome (PRO)","Allogeneic Blood and Marrow Transplantation (BMT)","CAR T Cell Therapy",[25,30,31,32,33,34,35],"CAR-T cell therapy","Allogenic BMT","Patient Reported Outcome","Leukemia","Multiple Myeloma","Lymphoma","NOT_YET_RECRUITING","2025-12-04",{"date":39,"type":40},"2025-12-17","ACTUAL",{"date":42,"type":21},"2026-02-15",{"date":44,"type":21},"2027-04-01",{"name":46,"class":47},"Associazione Qol-one","OTHER"]